Abstract
A model of experimentally induced inflammatory bowel disease (IBD) featuring colitis, originally devised by Onderdonk and co-workers in guinea pigs, was modified to establish the optimal conditions for ulcer development. Upon varying the time of subcutaneous immunization withBacteroides vulgatus and concomitant oral administration of aciddegradediota-carrageenan and viableB. vulgatus, it was found that the optimal times of administering these agents were one to two weeks and five to six days, respectively. Light microscopy of the colon and cecum of the guinea pigs given the optimized treatment for ulcer induction revealed pronounced edema, inflammation, and lesions of the mucosa. Transmission electron microscopy of the mucosa from these animals showed the presence of large numbers of leukocytes in the subepithelial region, the majority being polymorphonuclear neutrophils which possessed large electron-dense granules or rods. Oral administration of 300 mg/kg/day sulfasalazine (salicylazosulfapyridine) for 14 days to guinea pigs given the optimized treatment for ulcer induction failed to reduce the numbers of ulcers or the histopathology gradings and fine structural changes of the mucosal inflammatory changes, but did reduce the symptoms of diarrhea.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Sleisenger MH: Pathophysiology of the gastrointestinal tract.In Pathophysiology: The Biologic Principles of Disease. LH Smith, SO Thie (eds). Philadelphia, WB Saunders, 1981, pp 1506–1689
Taffet SL, Das KM: Salfasalazine. Adverse effects and desensitization. Dig Dis Sci 28:833–842, 1983
Dawson IMP: Atlas of Gastrointestinal Pathology as Seen on Biopsy, Vol 6. MTP Press, Boston, 1983
Riddell RH: Inflammation bowel disease. Differential diagnosis and cancer of the small and large bowel. Dig Dis Sci 30:11S-13S, 1985
Jewell DP, MacLellan ICM: Circulating immune complexes in inflammatory bowel disease. Clin Exp Immunol 14:219–226, 1973
Nielsen H, Binder V, Daugtarty H, Svehag SE: Circulating immune complexes in ulcerative colitis. I. Correlation to disease activity. Clin Exp Immunol 31:72–80, 1978
Danis VA, Harries AD, Heatley RV:In vitro immunoglobulin secretion by normal human gastrointestinal tissues, and alterations in patients with inflammatory bowel diseases. Clin Exp Immunol 56:159–166, 1984
Winship DH: Immune complexes in inflammatory bowel disease: cause or coincidence? J Lab Clin Med 97:313–315, 1981
Pfeiffer CJ: Animals models of colitis.In Animal Models for Intestinal Disease. CJ Pfeiffer (ed). Boca Raton, Florida, CRC Press, 1986, pp 147–160
Strober W: Animal models of inflammatory bowel diseases—an overview. Dig Dis Sci 30:3S-10S, 1985
Onderdonk AB: Experimental models for ulcerative colitis. Dig Dis Sci 30:40S-44S, 1985
Kirsner JB: Experimental “colitis” with particular reference to hypersensitivity reactions in the colon. Gastroenterology 40:302–312, 1961
Kraft SC, Fitch FW, Kirsner JB: Histologic and immunohistochemical features of Auer “colitis” in rabbits. Am J Pathol 43:913–923, 1963
Onderdonk AB, Cisneros RL, Bronson RT: Enhancement of experimental ulcerative colitis by immunization withBacteriodes vulgatus. Infect Immun 42:783–788, 1983
Onderdonk AB, Steeves RM, Cisneros RL, Bronson RT: Adoptive transfer of immune enhancement of experimental ulcerative colitis. Infect Immun 46:64–67, 1984
Onderdonk AB, Bronson R, Cisneros R: Comparison ofBacteriodes vulgatus strains in the enhancement of experimental ulcerative colitis. Infect Immun 55:835–836, 1987
Anver MR, Cohen BJ: Animal model of human disease. Ulcerative colitis. Am J Pathol 84:431–434, 1976
Norris AA, Lewis AJ, Zeitlin IJ: Inability of degraded carrageenan fractions to induce inflammatory bowel ulceration in the guinea pig. J Pharm Pharmacol 33:612–613, 1981
Reynolds ES: The use of lead citrate at high pH as an electron opaque stain in electron microscopy. J Cell Biol 17:208–212, 1963
Watson ML: Staining of tissue sections for electron microscopy with heavy metals. J Biophys Biochem Cytol 4:475–478, 1958
Sharon P, Stenson WF: Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease. Gastroenterology 88:56–63, 1985
Broughton-Smith NK, Whittle BJR: Increased metabolism of arachidonic acid in an immune model of colitis in guinea pigs. Br J Pharmacol 86:439–446, 1985
Hoult JRS: Sulphasalazine: Mode of action and side-effects in rheumatoid arthritis and ulcerative colitis.In Side Effects of Anti-Inflammatory Drugs, Vol 2. KD Rainsford, GP Velo (eds). Lancaster, MTP Press, 1987, pp 223–231
Rainsford KD: Inhibitors of prostaglandin and leukotriene production.In Prostaglandins: Biology and Chemistry of Prostaglandins and Related Eicosanoids. PB Curtis-Prior (ed). London, Churchill-Livingstone, 1988, pp 52–68
Miyachi Y, Yoshioka A, Imamura S, Niwa Y: Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 28:190–195, 1987
Shields HM, Bates ML, Goldman H, Zuckerman GR, Mills BA, Best CJ, Bair FA, Goran DA, DeSchryver-Kecskemeti K: Scanning electron microscopic appearance of chronic ulcerative colitis with and without dysplasia. Gastroenterology 89:62–72, 1985
Nicklin S, Miller K: Effect of orally administered food-grade carrageenans on antibody-mediated and cell-mediated immunity in the inbred rat. Food Chem Toxicol 22:615–621, 1984
Sugawara I, Ishizaka S: Desulfated carrageenans and cytotoxicity of human monocytes. Agents Actions 13:354–359, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oestreicher, P., Nielsen, S.T. & Rainsford, K.D. Inflammatory bowel disease induced by combined bacterial immunization and oral carrageenan in guinea pigs. Digest Dis Sci 36, 461–470 (1991). https://doi.org/10.1007/BF01298875
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01298875